Immunomic Therapeutics at the 2010 OneMedForum
Dr. William G. Hearl, CEO of Immunomic Therapeutics, discusses his company with OneMedTV correspondent Alicia Ontiveros at the 2010 OneMedForum in San Francisco.
Dr. William G. Hearl, CEO of Immunomic Therapeutics, discusses his company with OneMedTV correspondent Alicia Ontiveros at the 2010 OneMedForum in San Francisco.
Ron Andrews, CEO of Clarient, Inc., discusses his company with William Dawson of LifeTech Capital at the 2010 OneMedForum in San Francisco.
Michael N. Liebman, President and Managing Director of Strategic Medicine, discusses his company with OneMedTV correspondent Alicia Ontiveros at the 2010 OneMedForum in San Francisco.
Denis Corin, President of TapImmune, Inc., discusses his company with William Dawson of LifeTech Capital at the 2010 OneMedForum in San Francisco.
Jeff Eliot Margolis, CFO of Xintria Pharmaceutical Corporation, discusses his company with William Dawson of LifeTech Capital at the 2010 OneMedForum in San Francisco.
The significant differences between Echo Therapeutics’ Symphony system and the competition is the needle-free transdermal biosensor, clinical trials in the hospital setting and biosensor life.
Biomoda’s CyPath diagnostic assay is based on molecular marker technology originally developed at the Los Alamos National Laboratory.
Genomic Health, a developer of genomics-based diagnostic tests, announced on Thursday the worldwide availability of its Oncotype DX Colon Cancer Test.
The U.S. Food and Drug Administration (FDA) has approved the first drug designed to improve walking in adults with multiple sclerosis.
After receiving guidance from U.S. regulators, pharmaceutical company Depomed has announced a late-stage trial of its drug candidate for menopausal hot flashes.
Copyright © 2026 | WordPress Theme by MH Themes